ThomasC.BlevinsMD

Endocrinology • Austin, TX

Diabetes, Lipid Metabolism

Endocrinologist, Texas Diabetes & Endocrinology

Join to view full profile

Dr. Blevins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Blevins' full profile

Already have an account?

Office
6500 N Mopac Expy
Bldg 3
Austin, TX 78731
Phone+1 512-458-8400

Fax+1 512-458-8593

Education & Training

Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1984 - 1986
Baylor College of MedicineResidency, Internal Medicine, 1981 - 1984
Baylor College of MedicineClass of 1981

Certifications & Licensure

TX State Medical License 1981 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Diabetes Recognition Program National Committee for Quality Assurance, 2012-2015
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FACE) American Association of Clinical Endocrinology
Diabetes Care Recognition Health Care Incentives Improvement Institute
Join now to see all

Clinical Trials

A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port Start of enrollment: 2006 Oct 01
Completed
Not Applicable
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port Start of enrollment: 2009 Aug 01
Terminated
Not Applicable
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
Completed
Phase 2
A Study of LY2623091 in Participants With High Blood Pressure Start of enrollment: 2014 Aug 01
Completed
Phase 2
FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump Start of enrollment: 2019 Jun 11
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

196 citations
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
John B. Buse, Tina Vilsbøll, Jerry Thurman, Thomas Blevins, Irene H. Langbakke
Diabetes Care. 2014-11-01
134 citations
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus
George Grunberger, Jennifer L. Sherr, Myriam Allende, Thomas Blevins, Bruce W. Bode
Endocrine Practice. 2021-06-01
419 citations
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C.W. Lau
Lancet. 2017-04-08

Journal Articles

Efficacy and Safety of MYL‐1501D Versus Insulin Glargine in Patients with Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 Study
Thomas Blevins, MD, Diabetes, Obesity and Metabolism

Press Mentions

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes AssociationJune 25th, 2021
Mylan and Biocon Biologics Announce Launch of Semglee™ (Insulin Glargine Injection) in the U.S. To Expand Access for Patients Living with DiabetesAugust 31st, 2020
Ideal Protein Announces Inaugural Medical Advisory BoardApril 12th, 2016
Join now to see all

Professional Memberships

American Association of Clinical Endocrinologists - AACE
Fellow